We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Vein hopes

22 January 2018 By Liam Proud

The French pharma giant is buying U.S. haemophilia group Bioverativ at a whopping 64 pct premium. Sanofi reckons the returns will clear its hurdle rate in three years, but hasn’t explained how. Roche’s rival drug means the deal could end up like Shire’s ill-fated Baxalta swoop.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)